ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0179

Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Tomography Imaging Predicts Adverse Events in Patients with Autoimmune Rheumatic Disease

Attila Feher1, Nabil Boutagy1, Evangelos Oikonomou1, Yi-Hwa Liu1, Edward Miller1, Albert Sinusas1 and Monique Hinchcliff2, 1Yale School of Medicine, New Haven, CT, 2Yale School of Medicine, Westport, CT

Meeting: ACR Convergence 2021

Keywords: fibrosis, Imaging, microvasculature, PET, Scleroderma, Systemic

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Imaging of Rheumatic Diseases Poster (0149–0182)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Coronary microvascular dysfunction (CMVD) has been described in patients with autoimmune rheumatic disease (ARD). By noninvasive evaluation of myocardial blood flow (MBF) and myocardial flow reserve (MFR) quantification, positron emission tomography (PET) imaging has emerged as the noninvasive gold standard CMVD assessment. However, to date, no large studies have evaluated PET-derived MFR in ARD patients. It is also unknown whether MFR can predict adverse events in this population.

Methods: Patients with ARD without coronary artery disease who underwent dynamic rest-stress 82Rubidium PET from 05/2012-05/2019 for a clinical indication were retrospectively studied and compared to patients without ARD matched for age, gender and comorbidities. The association between MFR and a composite endpoint of mortality or myocardial infarction (MI) or heart failure (HF) admission was evaluated with time to event and Cox-regression analyses.

Results: In 101 patients with ARD (88% female, age: 62±10 years), stress MBF did not significantly differ between patients with ARD (median with interquartile range [IQR], 1.68 [IQR: 1.39 – 2.07]) compared to those without ARD (1.49 [IQR: 1.26 – 1.93]) (Figure 1A). Conversely, rest MBF was significantly higher in ARD patients (1.00 [IQR: 0.84 – 1.21]) compared to those without an ARD diagnosis (0.80 [IQR: 0.68 – 0.99]) (Figure 1B). Consequently, MFR was significantly reduced in ARD patients compared to patients without ARD (1.68 [IQR: 1.34 – 2.05] vs. 1.86 [IQR: 1.58 – 2.28]) (Figure 1C). MFR did not differ among subtypes of ARDs. During the median follow-up of 3.8 years, there were twelve deaths, two MIs and 18 HF admissions in ARD patients. In survival analysis, patients with ARD and low MFR (MFR< 1.5) had decreased event-free survival for the combined endpoint, when compared to patients with and without ARD and normal MFR (MFR >1.5) and when compared to patients without ARD and low MFR, after adjustment for the non-laboratory-based Framingham risk score, rest left ventricular ejection fraction, severe coronary calcification, and the presence of medium/large perfusion defects (Figure 2). In Cox-regression analysis, ARD diagnosis and MFR were both independent predictors of adverse events in ARD patients along with congestive HF diagnosis and presence of medium/large stress perfusion defects on PET (Figure 3).

Conclusion: Patients with ARD have significantly reduced PET MFR compared to age-, gender- and comorbidity-matched patients without ARD. Reduced PET MFR and ARD diagnosis are both independent predictors of adverse outcomes.

Figure 1. Stress (Panel A) and rest (Panel B) myocardial blood flow (MBF) and myocardial flow reserve values (Panel C) in patients with or without autoimmune rheumatic disease (ARD)

Figure 2. Kaplan Meier plots for event-free survival for the combined end point of death, myocardial infarction (MI) or heart failure (HF) admission in patients with autoimmune rheumatic disease (ARD) based on myocardial flow reserve (MFR).

Figure 3. Forest plot of hazard ratios (HR) for the combined end point of death, myocardial infarction or heart failure admission in multivariate Cox proportional hazards regression models in patients with autoimmune rheumatic disease. CT: computed tomography, PET: positron emission tomography


Disclosures: A. Feher, None; N. Boutagy, None; E. Oikonomou, None; Y. Liu, None; E. Miller, None; A. Sinusas, None; M. Hinchcliff, None.

To cite this abstract in AMA style:

Feher A, Boutagy N, Oikonomou E, Liu Y, Miller E, Sinusas A, Hinchcliff M. Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Tomography Imaging Predicts Adverse Events in Patients with Autoimmune Rheumatic Disease [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/impaired-myocardial-flow-reserve-on-82rubidium-positron-emission-tomography-imaging-predicts-adverse-events-in-patients-with-autoimmune-rheumatic-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impaired-myocardial-flow-reserve-on-82rubidium-positron-emission-tomography-imaging-predicts-adverse-events-in-patients-with-autoimmune-rheumatic-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology